[8] Novo Nordisk announced late at the 2025 European Association for the Study of Diabetes (EASD) annual meeting that in the REDEFINE 1 study, [9] cagrilintide provided clinically significant weight loss, with a mean reduction in body weight of 11.8% compared to 2.3% with placebo after 68 weeks, considering adherence of all participants to treatment
AOD-9604 minimizes systemic effects by not interacting with growth hormone receptors, in contrast to human growth hormone, from which it is produced
The pro-cognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system
While generally safe, certain individuals should consult a healthcare professional before starting: Pregnant or breastfeeding women People with chronic medical conditions Individuals on long-term medication Those with known allergies to marine sources This is a precaution, not a warning informed use is always the safest approach
Apolipoprotein E binding drives structural and compositional rearrangement of mRNA-containing lipid nanoparticles
